References of "Beckers, Albert"
     in
Bookmark and Share    
Full Text
See detailLa déficience en FSH : actualités cliniques et thérapeutiques
VALDES SOCIN, Hernan Gonzalo ULiege; Pintiaux, Axelle ULiege; Delbaere, Anne et al

in Urologic (2017), 13(3), 16-22

L'hormone lutéinisante (LH) et l'hormone folliculostimulante (FSH) - hormones glycoprotéiques hypophysaires - régulent de concert la production de stéroïdes sexuels et la reproduction. Les stéroïdes ... [more ▼]

L'hormone lutéinisante (LH) et l'hormone folliculostimulante (FSH) - hormones glycoprotéiques hypophysaires - régulent de concert la production de stéroïdes sexuels et la reproduction. Les stéroïdes sexuels sont indispensables à la virilisation et à la féminisation, et participent également à la gamétogenèse (spermatogenèse chez l'homme et folliculogenèse chez la femme). Cet article sur le déficit en FSH fait suite à un article précédent publié dans Urologic décrivant le déficit en LH et ses conséquences sur la reproduction. [less ▲]

Detailed reference viewed: 104 (4 ULiège)
Full Text
See detailTekort aan luteïniserend hormoon : gevolgen voor de voortplanting
VALDES SOCIN, Hernan Gonzalo ULiege; NECHIFOR, Iulia ULiege; LIBIOULLE, Cécile ULiege et al

in Bloedvaten, Hart, Longen (2017), 22(9),

Detailed reference viewed: 13 (1 ULiège)
Full Text
See detailLa déficience en hormone lutéinisante (LH) : ses conséquences sur la reproduction
VALDES SOCIN, Hernan Gonzalo ULiege; NECHIFOR, Iulia ULiege; LIBIOULLE, Cécile ULiege et al

in Vaisseaux, Coeur, Poumons (2017), 22(9),

Detailed reference viewed: 14 (2 ULiège)
Full Text
See detailUse of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor.
VALDES SOCIN, Hernan Gonzalo ULiege; Almanza, Matilde Rubio; Fernandez-Ladreda, Mariana Tome et al

in Archives of Endocrinology and Metabolism (2017)

Neuroendocrine tumors (NETs) can secrete hormones, including ectopic secretions, but they have been rarely associated with malignant hypercalcemia. A 52-year-old man with a history of diabetes mellitus ... [more ▼]

Neuroendocrine tumors (NETs) can secrete hormones, including ectopic secretions, but they have been rarely associated with malignant hypercalcemia. A 52-year-old man with a history of diabetes mellitus was diagnosed with a pancreatic tumor. A pancreatic biopsy confirmed a well-differentiated pancreatic NET (pNET). The patient subsequently developed liver metastasis and hypercalcemia with high 1,25 OH vitamin D and suppressed parathyroid hormone (PTH) levels. Hypercalcemia was refractory to chemotherapy, intravenous saline fluids, diuretics, calcitonin and zoledronate. Cinacalcet administration (120 mg/day) resulted in a significant calcium reduction. Hypocalcemia was observed when sunitinib was added three months later and cinacalcet was stopped. Subsequently, the calcium and PTH levels normalized. After six months, we observed 20% shrinkage of the pancreatic tumor and necrosis of a liver metastasis. Cinacalcet is an allosteric activator of the calcium receptor agonist, and it is used for severe hypercalcemia in patients with primary (benign and malignant) hyperparathyroidism. In this patient, cinacalcet demonstrated a calcium lowering effect, normalized hypophosphatemia, and improved the clinical condition of the patient. The mechanism through which cinacalcet improved PTH-rp mediated hypercalcemia is still unclear, but studies have suggested that a potential mechanism is the activation of calcitonin secretion. Sunitinib is an oral multi-targeted tyrosine kinase inhibitor used to treat advanced pNETs. The hypocalcemic effects of sunitinib have not been previously described in a patient with pNET. Here, we report for the first time the successful combination of cinacalcet and sunitinib in the treatment of a pNET patient presenting with malignant hypercalcemia. [less ▲]

Detailed reference viewed: 54 (4 ULiège)
Full Text
Peer Reviewed
See detailHistologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort Study.
Lecomte, Pierre ULiege; Binquet, C.; Le Bras, M. et al

in World Journal of Surgery (2017)

OBJECTIVE: To evaluate the natural history of MEN1-related bronchial endocrine tumors (br-NETs) and to determine their histological characteristics, survival and causes of death. br-NETs frequency ranges ... [more ▼]

OBJECTIVE: To evaluate the natural history of MEN1-related bronchial endocrine tumors (br-NETs) and to determine their histological characteristics, survival and causes of death. br-NETs frequency ranges from 3 to 13% and may reach 32% depending on the number of patients evaluated and on the criteria required for diagnosis. METHODS: The 1023-patient series of symptomatic MEN1 patients followed up in a median of 48.7 [35.5-59.6] years by the Groupe d'etude des Tumeurs Endocrines was analyzed using time-to-event techniques. RESULTS: br-NETs were found in 51 patients (4.8%, [95% CI 3.6-6.2%]) and were discovered by imaging in 86% of cases (CT scan, Octreoscan, Chest X-ray, MRI). Median age at diagnosis was 45 years [28-66]. Histological examination showed 27 (53%) typical carcinoids (TC), 16 (31%) atypical carcinoids (AC), 2 (4%) large cell neuroendocrine carcinomas (LCNEC), 3(6%) small cell neuroendocrine carcinomas (SCLC), 3(6%) TC associated with AC. Overall survival was not different from the rest of the cohort (HR 0.29, [95% CI 0.02-5.14]). AC tended to have a worse prognosis than TC (p = 0.08). Seven deaths were directly related to br-NETs (three AC, three SCLC and one LCNEC). Patients who underwent surgery survived longer (p = 10-4) and were metastasis free, while 8 of 14 non-operated patients were metastatic. There were no operative deaths. CONCLUSIONS: Around 5% of MEN1 patients develop br-NETs. br-NETs do not decrease overall survival in MEN1 patients, but poorly differentiated and aggressive br-NETs can cause death. br-NETs must be screened carefully. A biopsy is essential to operate on patients in time. [less ▲]

Detailed reference viewed: 40 (6 ULiège)
Full Text
See detailLe gigantisme hypophysaire, une histoire de grandes personnes
PETIGNOT, Sandrine ULiege; BECKERS, Pablo ULiege; Rostomyan, Liliya ULiege et al

in Vaisseaux, Coeur, Poumons (2017), 22

Detailed reference viewed: 155 (47 ULiège)
Full Text
Peer Reviewed
See detailChanges in the management and comorbidities of acromegaly over three decades. The French Acromegaly Registry.
Maione, Luigi; Brue, Thierry; Beckers, Albert ULiege et al

in European Journal of Endocrinology (2017), 176(5), 645-655

CONTEXT: Acromegaly is a rare disease associated with chronic multisystem complications. National registries have been created in several countries. DESIGN: The French registry contains data on acromegaly ... [more ▼]

CONTEXT: Acromegaly is a rare disease associated with chronic multisystem complications. National registries have been created in several countries. DESIGN: The French registry contains data on acromegaly epidemiology, management and comorbidities recorded over more than three decades, retrospectively until 1999 and prospectively from 1999 until 2012. RESULTS: Data could be analyzed for 999 of the 1034 patients included in the registry (46% males). Disease control, defined as IGF-I normalization (adjusted for age and sex), was achieved in 75% of patients at the last follow-up visit. Half the patients with uncontrolled disease had IGF-I levels below 1.5 times the upper limit of normal (ULN). The proportion of patients with surgically cured disease did not change markedly over time, whereas the proportion of patients with uncontrolled disease fell and the proportion of patients with medically controlled disease rose. Cardiovascular, metabolic, respiratory and rheumatologic comorbidities and their outcomes were recorded for most patients, and no noteworthy overall deterioration was noted over time. Cancer occurred in 10% of patients, for a standardized incidence ratio of 1.34 (95% CI, 0.94-1.87) in men and 1.24 (0.77-1.73) in women. Forty-one patients died during follow-up, for a standardized mortality ratio of 1.05 (0.70-1.42). Most deaths were due to cancer. CONCLUSIONS: The majority of patients with acromegaly now have successful disease control thanks to multistep management. The incidence of comorbidities following diagnosis of acromegaly is very low. Life expectancy is now close to that of the general population, probably owing to better management of the GH/IGF-I excess and comorbidities. [less ▲]

Detailed reference viewed: 38 (6 ULiège)
Full Text
Peer Reviewed
See detailT2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective.
Potorac, Iulia ULiege; Beckers, Albert ULiege; BONNEVILLE, Jean-François ULiege

in Pituitary (2017), 20(1), 116-120

T2-weighted MRI signal intensity of GH-secreting pituitary adenomas is gaining recognition as a marker of disease characteristics and may be a predictor of response to treatment of acromegaly. Adenomas ... [more ▼]

T2-weighted MRI signal intensity of GH-secreting pituitary adenomas is gaining recognition as a marker of disease characteristics and may be a predictor of response to treatment of acromegaly. Adenomas that are T2-hypointense are more common, are smaller and are less likely to invade the cavernous sinus compared to the T2-iso and hyperintense tumors. T2-hypointense tumors are also accompanied by higher IGF1 values at baseline. When presurgical somatostatin receptor ligand (SRL) therapy is administered, T2-hypointense adenomas have better hormonal responses and have greater tumor shrinkage. Adjuvant SRL therapy of patients with T2-hypointense tumors that are uncured by surgery is also associated with a better hormonal response. We review the studies that have dealt with the T2-weighted signal intensity of GH-secreting pituitary tumors and elaborate on the details and nuances of this promising avenue of research. [less ▲]

Detailed reference viewed: 22 (5 ULiège)
Full Text
Peer Reviewed
See detailCabergoline for Cushing's disease: a large retrospective multicenter study.
Ferriere, A.; Cortet, C.; Chanson, P. et al

in European Journal of Endocrinology (2017), 176(3), 305-314

OBJECTIVE: The efficacy of cabergoline in Cushing's disease (CD) is controversial. The aim of this study was to assess the efficacy and tolerability of cabergoline in a large contemporary cohort of ... [more ▼]

OBJECTIVE: The efficacy of cabergoline in Cushing's disease (CD) is controversial. The aim of this study was to assess the efficacy and tolerability of cabergoline in a large contemporary cohort of patients with CD. DESIGN: We conducted a retrospective multicenter study from thirteen French and Belgian university hospitals. METHODS: Sixty-two patients with CD received cabergoline monotherapy or add-on therapy. Symptom score, biological markers of hypercortisolism and adverse effects were recorded. RESULTS: Twenty-one (40%) of 53 patients who received cabergoline monotherapy had normal urinary free cortisol (UFC) values within 12 months (complete responders), and five of these patients developed corticotropic insufficiency. The fall in UFC was associated with significant reductions in midnight cortisol and plasma ACTH, and with clinical improvement. Compared to other patients, complete responders had similar median baseline UFC (2.0 vs 2.5xULN) and plasma prolactin concentrations but received lower doses of cabergoline (1.5 vs 3.5 mg/week, P < 0.05). During long-term treatment (>12 months), cabergoline was withdrawn in 28% of complete responders because of treatment escape or intolerance. Overall, sustained control of hypercortisolism was obtained in 23% of patients for 32.5 months (19-105). Nine patients on steroidogenesis inhibitors received cabergoline add-on therapy for 19 months (1-240). Hypercortisolism was controlled in 56% of these patients during the first year of treatment with cabergoline at 1.0 mg/week (0.5-3.5). CONCLUSIONS: About 20-25% of CD patients are good responders to cabergoline therapy allowing long-term control of hypercortisolism at relatively low dosages and with acceptable tolerability. No single parameter, including the baseline UFC and prolactin levels, predicted the response to cabergoline. [less ▲]

Detailed reference viewed: 44 (6 ULiège)
Full Text
Peer Reviewed
See detailMRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
Eroukhmanoff, J.; Tejedor, I.; Potorac, Iulia ULiege et al

in European Journal of Endocrinology (2017), 176(3), 323-328

OBJECTIVE: Both antitumor and antisecretory efficacies of dopamine agonists (DA) make them the first-line treatment of macroprolactinomas. However, there is no guideline for MRI follow-up once prolactin ... [more ▼]

OBJECTIVE: Both antitumor and antisecretory efficacies of dopamine agonists (DA) make them the first-line treatment of macroprolactinomas. However, there is no guideline for MRI follow-up once prolactin is controlled. The aim of our study was to determine whether a regular MRI follow-up was necessary in patients with long-term normal prolactin levels under DA. PATIENTS AND METHODS: We conducted a retrospective multicenter study (Marseille, Paris La Pitie Salpetriere and Nancy, France; Liege, Belgium) including patients with macroprolactinomas (largest diameter: >10 mm and baseline prolactin level: >100 ng/mL) treated by dopamine agonists, and regularly followed (pituitary MRI and prolactin levels) during at least 48 months once normal prolactin level was obtained. RESULTS: In total, 115 patients were included (63 men and 52 women; mean age at diagnosis: 36.3 years). Mean baseline prolactin level was 2224 +/- 6839 ng/mL. No significant increase of tumor volume was observed during the follow-up. Of the 21 patients (18%) who presented asymptomatic hemorrhagic changes of the macroprolactinoma on MRI, 2 had a tumor increase (2 and 7 mm in the largest size). Both were treated by cabergoline (1 mg/week) with normal prolactin levels obtained for 6 and 24 months. For both patients, no further growth was observed on MRI during follow-up at the same dose of cabergoline. CONCLUSION: No significant increase of tumor size was observed in our patients with controlled prolactin levels on DA. MRI follow-up thus appears unnecessary in patients with biologically controlled macroprolactinomas. [less ▲]

Detailed reference viewed: 43 (4 ULiège)
Full Text
Peer Reviewed
See detailA multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues
Franck, Sanne Elisabeth; Korevaar, Tim; PETROSSIANS, Patrick ULiege et al

in European Journal of Endocrinology (2017)

Background: Effective treatment of acromegaly with pegvisomant (PEGV), a growth hormone receptor antagonist, requires an appropriate dose titration. PEGV doses vary widely among individual patients, and ... [more ▼]

Background: Effective treatment of acromegaly with pegvisomant (PEGV), a growth hormone receptor antagonist, requires an appropriate dose titration. PEGV doses vary widely among individual patients, and various covariates may affect its dosing and pharmacokinetics. Objective: To identify predictors of the PEGV dose required to normalize insulin-like growth factor I (IGF-I) levels during PEGV monotherapy and in combination with long-acting somatostatin analogues (LA-SSAs). 188) were meta-analysed as a form of external replication to study the predictors of PEGV dosing in addition to LA-SSA, the LAS (n=83) was used to study the predictors of PEGV monotherapy dosing. Multivariable regression models were used to identify predictors of the PEGV dose required to normalize IGF-I levels. <0.001, p=<0.001, p=0.028 and p=0.047, respectively). Taken together, these characteristics predicted the PEGV normalization dose correctly in 63.3% of all patients within a range of +/- 60 mg/week (21.3% within a range of +/- 20 mg/week). For monotherapy, only weight was associated with the PEGV normalization dose (p=<0.001) and predicted this dosage correctly in 77.1% of all patients within a range of +/- 60 mg/week (31.3% within a range of +/- 20 mg/week). Conclusion: In this study, we show that IGF-I levels, weight, height and age can contribute to define the optimal PEGV dose in order to normalize IGF-I levels in addition to LA-SSA. For PEGV monotherapy, only the patient's weight was associated with the IGF-I normalization PEGV dosage. [less ▲]

Detailed reference viewed: 117 (10 ULiège)
Full Text
Peer Reviewed
See detailThe role of AIP mutations in pituitary adenomas: 10 years on
Daly, Adrian ULiege; BECKERS, Albert ULiege

in Endocrine (2016)

Detailed reference viewed: 55 (6 ULiège)
Peer Reviewed
See detailScreening for genetic causes of GH hypersecretion
Rostomyan, Liliya ULiege; Beckers, Albert ULiege

Conference (2016, November)

Detailed reference viewed: 18 (4 ULiège)
See detailThe history of XLAG syndrome (2015)
Beckers, Albert ULiege

Scientific conference (2016, November)

Detailed reference viewed: 45 (1 ULiège)
See detailApplying new developments in the genetic understanding of inherited pituitary adenoma.
Beckers, Albert ULiege

Scientific conference (2016, November)

Detailed reference viewed: 22 (1 ULiège)
Full Text
Peer Reviewed
See detailUne hypokaliémie à Liège
VALDES SOCIN, Hernan Gonzalo ULiege; EMONTS, Patrick ULiege; HAMOIR, Etienne ULiege et al

Conference (2016, October 15)

Detailed reference viewed: 71 (9 ULiège)
Full Text
Peer Reviewed
See detailProspective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
VROONEN, Laurent ULiege; Lancellotti, Patrizio ULiege; Garcia, Monica Tome et al

in Endocrine (2016)

Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated ... [more ▼]

Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated in Parkinson's disease patients treated with dopamine agonists. Retrospective studies in prolactinoma patients treated with cabergoline at lower doses did not show such an effect. However, few prospective data with long-term follow-up are available. The aim of this study was to assess the safety of cabergoline regarding cardiac valvular status during prospective follow-up in patients treated for prolactinoma or idiopathic hyperprolactinemia. We report here a series of 100 patients (71F; median age at diagnosis: 41.5 years) treated with cabergoline for endocrine diseases (prolactinoma n = 89, idiopathic hyperprolactinemia n = 11). All patients underwent complete transthoracic echocardiographic studies at baseline and during long-term prospective surveillance using the same equipment and performed by the same technicians. The median interval between baseline and last follow-up echocardiographic studies while on cabergoline was 62.5 months (interquartile range: 34.75-77.0). The median total duration of cabergoline treatment was 124.5 months (interquartile range: 80.75-188.75) and the median cumulative total dose of cabergoline was 277.8 mg (interquartile range : 121.4-437.8 mg) at last follow-up. We found no clinically relevant alterations in cardiac valve function or valvular calcifications with cabergoline treatment. Our data suggest that findings from retrospective analyses are correct and that cabergoline is a safe chronic treatment at the doses used typically in endocrinology. [less ▲]

Detailed reference viewed: 210 (13 ULiège)
Full Text
See detailSomatic mosaicism is implicated in the etiology of XLAG syndrome
Rostomyan, Liliya ULiege; Daly, Adrian ULiege; Yuan, Bo et al

in 26nd meeting of the Belgian Endocrine Society - Abstract book (2016, October)

Detailed reference viewed: 20 (4 ULiège)
Full Text
See detailFaut-il suivre par IRM hypophysaire les patients porteurs de macroprolactinome dont l'hypersécrétion est contrôlée médicalement ?
Eroukhmanoff, J; Tejedor, I; Potorac, Iulia ULiege et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 36 (1 ULiège)